
Opus Genetics, Inc. (NASDAQ:IRD – Free Report) – Analysts at Brookline Capital Markets raised their FY2026 earnings estimates for Opus Genetics in a research note issued to investors on Thursday, November 12th. Brookline Capital Markets analyst K. Raja now expects that the company will earn ($0.42) per share for the year, up from their prior estimate of ($0.87). The consensus estimate for Opus Genetics’ current full-year earnings is ($0.70) per share. Brookline Capital Markets also issued estimates for Opus Genetics’ FY2027 earnings at ($0.62) EPS.
Opus Genetics (NASDAQ:IRD – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.31). The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.55 million.
IRD has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, October 15th. TD Cowen began coverage on Opus Genetics in a research note on Wednesday, July 29th. They issued a “buy” rating on the stock. Zacks Research raised Opus Genetics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. JonesTrading boosted their price target on shares of Opus Genetics from $10.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Finally, BTIG Research reissued a “buy” rating and set a $12.00 target price on shares of Opus Genetics in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.29.
Check Out Our Latest Analysis on IRD
Opus Genetics Stock Performance
NASDAQ IRD opened at $4.04 on Tuesday. The firm has a market cap of $390.48 million, a P/E ratio of -2.59 and a beta of 0.80. Opus Genetics has a 52-week low of $1.70 and a 52-week high of $7.07. The business’s 50-day moving average price is $4.47 and its 200 day moving average price is $4.24. The company has a quick ratio of 12.19, a current ratio of 9.65 and a debt-to-equity ratio of 0.90.
Institutional Investors Weigh In On Opus Genetics
A number of hedge funds and other institutional investors have recently modified their holdings of IRD. AWM Investment Company Inc. boosted its stake in shares of Opus Genetics by 352.3% during the 3rd quarter. AWM Investment Company Inc. now owns 1,051,936 shares of the company’s stock worth $5,091,000 after acquiring an additional 819,346 shares in the last quarter. Marshall Wace LLP increased its stake in Opus Genetics by 62.5% in the 3rd quarter. Marshall Wace LLP now owns 3,161,606 shares of the company’s stock valued at $15,302,000 after purchasing an additional 1,215,997 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in Opus Genetics by 49.3% during the third quarter. Nantahala Capital Management LLC now owns 4,569,528 shares of the company’s stock worth $22,117,000 after purchasing an additional 1,508,169 shares during the last quarter. Blue Owl Capital Holdings LP acquired a new position in Opus Genetics during the third quarter worth $4,693,000. Finally, HighTower Advisors LLC acquired a new position in Opus Genetics during the third quarter worth $99,000. 14.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Opus Genetics
In other Opus Genetics news, CEO George Magrath sold 28,258 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $3.90, for a total transaction of $110,206.20. Following the transaction, the chief executive officer directly owned 2,010,636 shares in the company, valued at approximately $7,841,480.40. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 14,000 shares of the company’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $3.55, for a total transaction of $49,700.00. Following the transaction, the chief financial officer owned 542,375 shares in the company, valued at $1,925,431.25. The trade was a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 673,805 shares of company stock worth $3,213,582 over the last three months. 11.70% of the stock is currently owned by company insiders.
About Opus Genetics
Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company’s therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.
See Also
- Five stocks we like better than Opus Genetics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
